The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Reni-cel in severe SCD: updated results from the RUBY trial
Rabi Hanna, MD, Cleveland Clinic, Cleveland, OH, shares updated results from the RUBY trial (NCT04853576), which is investigating renizgamglogene autogedtemcel (reni-cel), an investigational gene-edited autologous hematopoietic stem cell therapy, in patients with severe sickle cell disease (SCD). Dr Hanna notes that the safety and efficacy of this therapy are promising, with patients demonstrating sustained normalization of total hemoglobin, increased fetal hemoglobin, significant reductions in pain scores, and improvements in physical activity. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
